Search
RPI-78M
go.drugbank.com/drugs/DB05740ExperimentalOther neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS). … RPI-78M is being developed for the treatment of multiple sclerosis (MS).
Calcium levulinate
go.drugbank.com/drugs/DB13800ApprovedThe relatively new calcium levulinate is produced from a direct reaction between L- or levulinic acid levulose and calcium hydroxide [L2765]. … Calcium levulinate can be used alone, or with calcium lactate, calcium chloride, and other compounds, either for pharmaceutical tablets, capsules, or injections preparation [L2765].
Mixtures: CALCİLES 225 MG+572 MG/10 ML ENJEKSİYONLUK ÇÖZELTİ, 5 ADET, CALPİNES 225 MG/10 ML + 572 MG/10 ML ENJEKSİYONLUK ÇÖZELTİ, 5 ADETAntihemophilic factor, human recombinant
go.drugbank.com/drugs/DB00025ApprovedInvestigationalHuman recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
International brands: Monarc-MProducts: ADVATE 3000 IU/5 ML IV ENJEKSIYON ICIN LIYOFILIZE TOZ ICEREN FLAKON, 1 ADET, ADVATE 250 IU/5 ML IV ENJEKSIYON ICIN LIYOFILIZE TOZ ICEREN FLAKON, 1 ADETEsterified estrogens
go.drugbank.com/drugs/DB09381ApprovedPreparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%.
Valine
go.drugbank.com/drugs/DB00161ApprovedInvestigationalNutraceuticalValine is a branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.
Synonyms: L-valin, L-valineMixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), AMINOPLASMAL-5% E INFUSIONToripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalOne mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsNaxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[L24454] This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,[A224604] making … [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015.
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses. … [A262924] On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsHuman interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigationalHuman interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992.
Phenylalanine
go.drugbank.com/drugs/DB00120ApprovedInvestigationalNutraceuticalPhenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.
Synonyms: L-Phenylalanine, 3-phenyl-L-alanineMixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), AMINOPLASMAL-5% E INFUSION